AstraZeneca, Breast Cancer and FDA
The clearance of Datroway comes months after the companies narrowed approval plans in lung cancer and opens up a market ...
Even before the FDA's recent approval of Dato-DXd in breast cancer, analysts predicted sales of the antibody-drug conjugate ...
LOS ANGELES, CA / ACCESS Newswire / January 22, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against AstraZeneca PLC ...
AstraZeneca PLC ADR closed 22.49% short of its 52-week high of $87.68, which the company reached on August 30th.
DXd, significantly improved median progression-free survival in a Phase III study but failed to do so for overall survival.
AstraZeneca has overhauled its local management in China, replacing Michael Lai with Alex Lin as the country's general ...
Sachin Jain, an analyst from Bank of America Securities, reiterated the Buy rating on AstraZeneca (AZN – Research Report). The associated price ...
AstraZeneca’s share price has fallen a long way from its record-breaking level last year, which indicates that I may be ...
From accelerating drug development and clinical trials to supercharging collaboration, machine learning-enhanced healthcare ...
AstraZeneca PLC AZN shares rallied 2.39% to £110.52 Tuesday, on what proved to be an all-around great trading session for the stock market, with the FTSE 100 Index UKX rising 0.33% to 8,548.29.
AstraZeneca (AZ) has received two separate recommendations from the National Institute for Health and Care Excellence (NICE) for use of its lung cancer drugs Tagrisso (osimertinib) and Imfinzi ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback